August 2, 2022 Media Coverage from ARCH Venture Partners | Share BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-related biotech, with ARCH jumping in
June 29, 2022 Media Coverage from ARCH Venture Partners | Share ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn
June 29, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces $2.975 Billion Fund XII to Create and Fund Early Stage Biotechnology Companies
June 7, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Promotions and New Appointment
June 6, 2022 Media Coverage from ARCH Venture Partners | Share ARCH-backed Resilience nabs its latest financing round, putting together a massive $625M Series D
May 19, 2022 Portfolio News from ARCH Venture Partners | Share Bob Nelsen-founded Resilience inks manufacturing pact with ARCH-backed Be Bio
May 16, 2022 Media Coverage from ARCH Venture Partners | Share John Maraganore named on Fierce’s Most Influential People in BioPharma list
May 9, 2022 Media Coverage from ARCH Venture Partners | Share John Maraganore’s “Reflections on Alnylam,” published in Nature Biotech
April 26, 2022 Portfolio News from ARCH Venture Partners | Share Irv Weissman’s lab spins out Pheast Therapeutics to target new ‘don’t eat me’ signal, $76M Series A led by ARCH Venture
April 14, 2022 Portfolio News from ARCH Venture Partners | Share ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer
March 14, 2022 Portfolio News from ARCH Venture Partners | Share Nutcracker Therapeutics with Bob Nelsen backing lands $167M to develop its own cancer drugs
March 9, 2022 Portfolio News from ARCH Venture Partners | Share Exclusive: ARCH and GV are building a large startup focused on mitochondrial diseases
